HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CIR To Consider Re-Opening Safety Review Of Benzyl Alcohol Due To New Data

This article was originally published in The Rose Sheet

Executive Summary

The Cosmetic Ingredient Review Expert Panel plans to evaluate new data regarding the inhalation toxicity of benzyl alcohol and benzoic acid during its next panel meeting June 28-29

You may also be interested in...



Hydroquinone Marketer Ceases Shipments After Warning From Texas

Obagi Medical is ceasing shipments of hydroquinone 4% products to doctors’ offices in Texas after the state's Department of State Health Services (DSHS) warned about compliance with federal and Texas laws.

Hydroquinone Marketer Ceases Shipments After Warning From Texas

Obagi Medical is ceasing shipments of hydroquinone 4% products to doctors’ offices in Texas after the state's Department of State Health Services (DSHS) warned about compliance with federal and Texas laws.

In Light Of European Ban, CIR Experts Will Revisit Disperse Blue 1

The Cosmetic Ingredient Review's Expert Panel plans to re-open a review of disperse blue 1 based largely on the European Union's decision to ban the hair-dye ingredient (see chart: "1Cosmetic Ingredient Review Report Status")

Latest Headlines
See All
UsernamePublicRestriction

Register

RS017016

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel